

Marco Matucci-Cerinic

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6857024/publications.pdf>

Version: 2024-02-01

292
papers

15,575
citations

41627

51
h-index

24511

114
g-index

296
all docs

296
docs citations

296
times ranked

13180
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management" by Snarskaya and Vasileva. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e37-e37.	0.5	2
2	Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e192-e192.	0.5	20
3	The Role of Pro-fibrotic Myofibroblasts in Systemic Sclerosis: From Origin to Therapeutic Targeting. <i>Current Molecular Medicine</i> , 2022, 22, 209-239.	0.6	14
4	Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 1141-1147.	0.9	8
5	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. <i>Rheumatology</i> , 2022, 61, 1600-1609.	0.9	53
6	Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral blood. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 379-385.	0.5	31
7	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 24-32.	1.0	25
8	One year later: The case of tocilizumab in COVID-19. <i>European Journal of Internal Medicine</i> , 2022, 95, 5-6.	1.0	7
9	Lung ultrasound B-lines in systemic sclerosis: cut-off values and methodological indications for interstitial lung disease screening. <i>Rheumatology</i> , 2022, 61, S156-S164.	0.9	11
10	The positive side of the coin: Sars-Cov-2 pandemic has taught us how much Telemedicine is useful as standard of care procedure in real life. <i>Clinical Rheumatology</i> , 2022, 41, 573-579.	1.0	9
11	Development and validation of a patient-reported outcome measure for systemic sclerosis: the EULAR Systemic Sclerosis Impact of Disease (SclerID) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 507-515.	0.5	10
12	Bone Marrow Edema. <i>Journal of Bone and Joint Surgery - Series A</i> , 2022, 104, 189-200.	1.4	8
13	Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology. <i>Journal of Rheumatology</i> , 2022, 49, 176-185.	1.0	12
14	Information Survey on the Use of Complementary and Alternative Medicine. <i>Medicina (Lithuania)</i> , 2022, 58, 125.	0.8	2
15	Early diagnosis of systemic sclerosis, where do we stand today?. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 1-3.	1.3	3
16	Shoulder impingement syndrome in water polo players: muscle shortening manoeuvre controls pain intensity, recovers function and normalizes sonographic parameters. <i>Journal of Ultrasound</i> , 2022, 25, 667-673.	0.7	1
17	Improvements of vascular outcomes in systemic sclerosis: halfway through, but still far to go. <i>Rheumatology</i> , 2022, , .	0.9	0
18	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 103-112.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation. <i>Rheumatology</i> , 2022, 61, 4409-4419.	0.9	10
20	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 3-11.	0.4	12
21	Decreased Serum Levels of SIRT1 and SIRT3 Correlate with Severity of Skin and Lung Fibrosis and Peripheral Microvasculopathy in Systemic Sclerosis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1362.	1.0	10
22	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	0.9	20
23	Effectiveness of SB4 transition from originator etanercept in rheumatoid arthritis and axial spondyloarthritis: A subgroup analysis from the BENEFIT study. <i>Rheumatology and Immunology Research</i> , 2022, 3, 31-37.	0.2	0
24	The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis. <i>Journal of Multidisciplinary Healthcare</i> , 2022, Volume 15, 815-824.	1.1	6
25	The added value of a European Reference Network on rare and complex connective tissue and musculoskeletal diseases: insights after the first 5 years of the ERN ReCONNET.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
26	Sjögren's syndrome and other rare and complex connective tissue diseases: an intriguing liaison.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
27	Case Report: Bullous Pemphigoid Associated With Morphea and Lichen Sclerosus: Coincidental Diseases or Pathogenetic Association?. <i>Frontiers in Immunology</i> , 2022, 13, 887279.	2.2	2
28	Predictive model of risk and severity of enteritis in systemic lupus erythematosus. <i>Lupus</i> , 2022, 31, 1226-1236.	0.8	5
29	Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies. <i>Current Pharmaceutical Design</i> , 2022, 28, 2022-2028.	0.9	7
30	The Renal Resistive Index: A New Biomarker for the Follow-up of Vascular Modifications in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 241-246.	1.0	7
31	The Challenge of Very Early Systemic Sclerosis: A Combination of Mild and Early Disease?. <i>Journal of Rheumatology</i> , 2021, 48, 82-86.	1.0	15
32	Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e37-e37.	0.5	71
33	Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression. <i>Clinical Rheumatology</i> , 2021, 40, 1903-1912.	1.0	12
34	Edema-like marrow signal intensity: a narrative review with a pictorial essay. <i>Skeletal Radiology</i> , 2021, 50, 645-663.	1.2	28
35	Infection or Autoimmunity? The Clinical Challenge of Interstitial Lung Disease in Systemic Sclerosis During the COVID-19 Pandemic. <i>Journal of Rheumatology</i> , 2021, 48, 790-792.	1.0	2
36	Patient preferences for systemic sclerosis treatment: A descriptive study within an Italian cohort. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 165-169.	1.0	2

#	ARTICLE	IF	CITATIONS
37	COVID-19 and systemic sclerosis: Rising to the challenge of a pandemic. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 58-65.	1.0	17
38	Rehabilitation of the face and temporomandibular joint in systemic sclerosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110201.	1.2	4
39	The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET. <i>Nature Reviews Rheumatology</i> , 2021, 17, 177-184.	3.5	35
40	Epidemiology of systemic sclerosis: a multi-database population-based study in Tuscany (Italy). <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 90.	1.2	9
41	Prognostic role of KL6 in SSc-ILD patients with pleuroparenchymal fibroelastosis. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13543.	1.7	9
42	ANCA in systemic sclerosis, when vasculitis overlaps with vasculopathy: a devastating combination of pathologies. <i>Rheumatology</i> , 2021, 60, 5509-5516.	0.9	10
43	Interleukin-1 and Systemic Sclerosis: Getting to the Heart of Cardiac Involvement. <i>Frontiers in Immunology</i> , 2021, 12, 653950.	2.2	26
44	COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. <i>Lancet Rheumatology, The</i> , 2021, 3, e166-e168.	2.2	25
45	Combined lung and cardiac ultrasound in COVID-related acute respiratory distress syndrome. <i>Internal and Emergency Medicine</i> , 2021, 16, 1779-1785.	1.0	13
46	Ultrasonographic imaging of systemic sclerosis digital ulcers: A systematic literature review and validation steps. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 425-429.	1.6	2
47	A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA Dermatology</i> , 2021, 157, 851-858.	2.0	12
48	The target on B cells in Systemic Sclerosis: a "midsummer dream" to extinguish inflammation and prevent early disease progression to fibrosis. <i>Clinical Rheumatology</i> , 2021, 40, 2529-2533.	1.0	5
49	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201594.	1.0	6
50	New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. <i>Expert Opinion on Investigational Drugs</i> , 2021, 30, 635-652.	1.9	28
51	Arthritis after SARS-CoV-2 infection. <i>Lancet Rheumatology, The</i> , 2021, 3, e324-e325.	2.2	32
52	Prediction and primary prevention of major vascular complications in systemic sclerosis. <i>European Journal of Internal Medicine</i> , 2021, 87, 51-58.	1.0	9
53	Exploring the Oral Microbiome in Rheumatic Diseases, State of Art and Future Prospective in Personalized Medicine with an AI Approach. <i>Journal of Personalized Medicine</i> , 2021, 11, 625.	1.1	20
54	New Insights into Profibrotic Myofibroblast Formation in Systemic Sclerosis: When the Vascular Wall Becomes the Enemy. <i>Life</i> , 2021, 11, 610.	1.1	14

#	ARTICLE	IF	CITATIONS
55	The emerging challenge of pain in systemic sclerosis: Similarity to the pain experience reported by Sjögren's syndrome patients. <i>Rheumatology and Immunology Research</i> , 2021, 2, 113-119.	0.2	0
56	Peripheral neuropathy in systemic lupus erythematosus: what can neuromuscular ultrasonography (NMUS) tell us? A cross-sectional study. <i>Lupus Science and Medicine</i> , 2021, 8, e000521.	1.1	2
57	Pulmonary magnetic resonance imaging in systemic sclerosis: a jump in the future to unravel inflammation in interstitial lung disease. <i>Clinical Rheumatology</i> , 2021, 40, 3461-3464.	1.0	6
58	Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. <i>Rheumatology International</i> , 2021, 41, 1743-1753.	1.5	24
59	Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. <i>Immuno</i> , 2021, 1, 253-263.	0.6	11
60	The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases. <i>Arthritis Research and Therapy</i> , 2021, 23, 212.	1.6	16
61	Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. <i>Molecules</i> , 2021, 26, 5789.	1.7	23
62	Association between central nervous system stimulants used to treat attention deficit hyperactivity disorder (ADHD) and Raynaud's phenomenon: A scoping review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1200-1204.	1.6	10
63	Similarities between COVID-19 and systemic sclerosis early vasculopathy: A "viral" challenge for future research in scleroderma. <i>Autoimmunity Reviews</i> , 2021, 20, 102899.	2.5	15
64	Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110336.	1.2	6
65	Adipose-derived stem cells: Pathophysiologic implications <i>vs</i> therapeutic potential in systemic sclerosis. <i>World Journal of Stem Cells</i> , 2021, 13, 30-48.	1.3	19
66	Impairment in the telocyte/CD34 ⁺ stromal cell network in human rheumatoid arthritis synovium. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 2274-2278.	1.6	10
67	In search for the ideal anatomical composition of vascularised human skin equivalents for systemic sclerosis translational research: should we recruit the telocytes?. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e149-e149.	0.5	6
68	Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. <i>Autoimmunity Reviews</i> , 2021, 20, 102981.	2.5	9
69	Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. <i>Diagnostics</i> , 2021, 11, 2165.	1.3	7
70	Scleroderma-like Impairment in the Network of Telocytes/CD34 ⁺ Stromal Cells in the Experimental Mouse Model of Bleomycin-Induced Dermal Fibrosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12407.	1.8	8
71	Systematic Literature Review and Expert Opinion for the Use of Viscosupplementation with Hyaluronic Acid in Different Localizations of Osteoarthritis. <i>Orthopedic Research and Reviews</i> , 2021, Volume 13, 255-273.	0.7	9
72	Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS). <i>Lancet Rheumatology</i> , The, 2021, 3, e834-e843.	2.2	42

#	ARTICLE	IF	CITATIONS
73	Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110596.	1.2	14
74	Computed Tomography Predictors of Mortality or Disease Progression in Systemic Sclerosis—Interstitial Lung Disease: A Systematic Review. Frontiers in Medicine, 2021, 8, 807982.	1.2	8
75	A candidate gene study reveals association between a variant of the SRp55 splicing factor gene and systemic sclerosis. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
76	Immune dysfunction in COVID-19 and judicious use of antirheumatic drugs for the treatment of hyperinflammation. Turkish Journal of Medical Sciences, 2021, 51, 3391-3404.	0.4	3
77	Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis. Journal of Rheumatology, 2020, 47, 249-254.	1.0	23
78	Patient perception of disease burden in diffuse cutaneous systemic sclerosis. Journal of Scleroderma and Related Disorders, 2020, 5, 66-76.	1.0	7
79	Pregnancy in Systemic Sclerosis: Results of a Systematic Review and Metaanalysis. Journal of Rheumatology, 2020, 47, 881-887.	1.0	32
80	Microparticles in systemic sclerosis, targets or tools to control fibrosis: This is the question!. Journal of Scleroderma and Related Disorders, 2020, 5, 6-20.	1.0	8
81	Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial. Arthritis and Rheumatology, 2020, 72, 125-136.	2.9	163
82	Musculoskeletal hand involvement in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2020, 50, 329-334.	1.6	26
83	Performance of ultra-high-frequency ultrasound in the evaluation of skin involvement in systemic sclerosis: a preliminary report. Rheumatology, 2020, 59, 1671-1678.	0.9	30
84	Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study. Rheumatology, 2020, 59, 1684-1694.	0.9	27
85	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology, 2020, 59, 2016-2023.	0.9	14
86	Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjögren's syndrome: A systematic review from the Italian Society of Rheumatology. Autoimmunity Reviews, 2020, 19, 102447.	2.5	59
87	Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease. Rheumatology, 2020, 59, 2024-2029.	0.9	21
88	Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). Rheumatology, 2020, 59, 1938-1948.	0.9	42
89	Recent advances steer the future of systemic sclerosis toward precision medicine. Clinical Rheumatology, 2020, 39, 1-4.	1.0	21
90	Germline genetic patterns underlying familial rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome highlight T cell-initiated autoimmunity. Annals of the Rheumatic Diseases, 2020, 79, 268-275.	0.5	55

#	ARTICLE	IF	CITATIONS
91	Study of vitamin D status and vitamin D receptor polymorphisms in a cohort of Italian patients with juvenile idiopathic arthritis. <i>Scientific Reports</i> , 2020, 10, 17550.	1.6	17
92	Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. <i>Lancet Rheumatology</i> , The, 2020, 2, e743-e753.	2.2	34
93	Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study. <i>Rheumatology</i> , 2020, 59, 3731-3736.	0.9	21
94	The power of the EUSTAR cohort: key findings to date and implications for management of systemic sclerosis patients. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 1065-1074.	1.3	5
95	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 963-974.	5.2	348
96	Pleuroparenchymal fibroelastosis in rheumatic autoimmune diseases: a systematic literature review. <i>Rheumatology</i> , 2020, 59, 3645-3656.	0.9	10
97	A Two-Step Immunomagnetic Microbead-Based Method for the Isolation of Human Primary Skin Teloocytes/CD34+ Stromal Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5877.	1.8	26
98	Prognostic Value of Lung Ultrasound B-Lines in Systemic Sclerosis. <i>Chest</i> , 2020, 158, 1515-1525.	0.4	50
99	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 724-726.	0.5	51
100	The contribution of epigenetics to the pathogenesis and gender dimorphism of systemic sclerosis: a comprehensive overview. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2091845.	1.2	13
101	Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review.. <i>European Journal of Internal Medicine</i> , 2020, 78, 17-25.	1.0	29
102	The systemic sclerosis patient in the COVID-19 era: the challenging crossroad between immunosuppression, differential diagnosis and long-term psychological distress. <i>Clinical Rheumatology</i> , 2020, 39, 2043-2047.	1.0	27
103	Effect of Dysmetabolisms and Comorbidities on the Efficacy and Safety of Biological Therapy in Chronic Inflammatory Joint Diseases. <i>Journal of Clinical Medicine</i> , 2020, 9, 1310.	1.0	5
104	The race against time to disclose lung inflammation in interstitial lung disease in systemic sclerosis: is PET scan the winning solution?. <i>Rheumatology</i> , 2020, 59, 1198-1199.	0.9	0
105	Quantitative analysis of pulmonary vasculature in systemic sclerosis at spirometry-gated chest CT. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1210-1217.	0.5	17
106	Patient experiences of digital ulcer development and evolution in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 2156-2158.	0.9	11
107	Raynaud phenomenon and digital ulcers in systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 208-221.	3.5	115
108	Digital ulcer debridement in systemic sclerosis: a systematic literature review. <i>Clinical Rheumatology</i> , 2020, 39, 805-811.	1.0	12

#	ARTICLE	IF	CITATIONS
109	Significant weight loss in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1123-1125.	0.5	11
110	COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 620-632.	0.4	351
111	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 618-625.	0.5	71
112	The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseases. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020, 12, 1759720X2096403.	1.2	21
113	Systemic sclerosis: To subset or not to subset, that is the question. <i>European Journal of Rheumatology</i> , 2020, 7, 222-227.	1.3	13
114	The emerging role of lung ultrasound in COVID-19 pneumonia. <i>European Journal of Rheumatology</i> , 2020, 7, S129-S133.	1.3	20
115	Risk of malignancy and biologic therapy in rheumatic inflammatory diseases: A single-center experience. <i>Rheumatology and Immunology Research</i> , 2020, 1, 39-45.	0.2	0
116	A special <i>European Journal of Rheumatology</i> issue on systemic sclerosis: What and why?. <i>European Journal of Rheumatology</i> , 2020, 7, S137-S138.	1.3	0
117	The Role of Imaging in COVID-19 Pneumonia Diagnosis and Management: Main Positions of the Experts, Key Imaging Features and Open Answers. <i>Journal of Cardiovascular Echography</i> , 2020, 30, S25-S30.	0.1	3
118	A special <i>European Journal of Rheumatology</i> issue on systemic sclerosis: What and why?. <i>European Journal of Rheumatology</i> , 2020, 7, 137-138.	1.3	0
119	Near-infrared spectroscopic imaging of the whole hand: A new tool to assess tissue perfusion and peripheral microcirculation in scleroderma. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 867-873.	1.6	12
120	Vasodilators and low-dose acetylsalicylic acid are associated with a lower incidence of distinct primary myocardial disease manifestations in systemic sclerosis: results of the DeSSciper inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1576-1582.	0.5	31
121	Enthesopathy and involvement of synovio-entheseal complex in systemic sclerosis: an ultrasound pilot study. <i>Rheumatology</i> , 2019, 59, 580-585.	0.9	6
122	Systemic Sclerosis Serum Steers the Differentiation of Adipose-Derived Stem Cells Toward Profibrotic Myofibroblasts: Pathophysiologic Implications. <i>Journal of Clinical Medicine</i> , 2019, 8, 1256.	1.0	11
123	Undifferentiated connective tissue disease: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000786.	1.8	28
124	TNF-Î±/TNF-R System May Represent a Crucial Mediator of Proliferative Synovitis in Hemophilia A. <i>Journal of Clinical Medicine</i> , 2019, 8, 939.	1.0	10
125	The Renal Resistive Index in systemic sclerosis: Determinants, prognostic implication and proposal for specific age-adjusted cut-offs. <i>European Journal of Internal Medicine</i> , 2019, 70, 43-49.	1.0	7
126	Very early systemic sclerosis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101428.	1.4	32

#	ARTICLE	IF	CITATIONS
127	Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1242-1248.	0.5	39
128	Blockade of CCL24 with a monoclonal antibody ameliorates experimental dermal and pulmonary fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1260-1268.	0.5	45
129	Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study. <i>Arthritis Research and Therapy</i> , 2019, 21, 130.	1.6	19
130	lloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. <i>Clinical and Experimental Medicine</i> , 2019, 19, 357-366.	1.9	23
131	Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 648-656.	0.5	79
132	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 979-987.	0.5	142
133	Idiopathic inflammatory myopathies: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000784.	1.8	19
134	Utilize lung ultrasound B-lines and KL-6 to monitor anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis-associated interstitial lung disease: a case report and literature review. <i>Clinical Rheumatology</i> , 2019, 38, 1433-1436.	1.0	4
135	Systemic sclerosis: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2019, 4, e000782.	1.8	91
136	AB0637â€¦IS VERY EARLY SYSTEMIC SCLEROSIS (SSC) A COMBINATION OF MILD AND EARLY DISEASE?. , 2019, , .		0
137	SAT0254â€¦.VASODILATOR THERAPY IN THE LONG TERM PREVENTION OF MYOCARDIAL MANIFESTATIONS IN SYSTEMIC SCLEROSIS (SSC): RESULTS FROM DESSCIPHER INCEPTION COHORT STUDY. , 2019, , .		0
138	FRI0302â€¦.SAFETY AND EFFICACY OF RITUXIMAB BIOSIMILAR IN SYSTEMIC SCLEROSIS: AN ITALIAN MULTICENTER STUDY. , 2019, , .		0
139	Pleuroparenchymal fibroelastosis in patients affected by systemic sclerosis. <i>Medicine (United States)</i> , 2019, 98, e16086.	0.4	4
140	Systemic Sclerosis Serum Significantly Impairs the Multi-Step Lymphangiogenic Process: In Vitro Evidence. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6189.	1.8	9
141	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , 2019, 18, 164-176.	2.5	44
142	Impact of EUSTAR standardized training on accuracy of modified Rodnan skin score in patients with systemic sclerosis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 96-102.	0.9	6
143	Preliminary Validation of the Digital Ulcer Clinical Assessment Score in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2019, 46, 603-608.	1.0	16
144	Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease â€” Scleroderma Clinical Trials Consortium. <i>Journal of Rheumatology</i> , 2019, 46, 78-84.	1.0	13

#	ARTICLE	IF	CITATIONS
145	18F-fluorodeoxyglucose positron-emission tomography/CT and lung involvement in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 577-578.	0.5	17
146	Imaging and serum biomarkers in connective tissue disease-associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levels. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 573-575.	0.5	9
147	Systemic sclerosis and primary biliary cholangitis: An overlapping entity?. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 111-117.	1.0	6
148	Decreased circulating lymphatic endothelial progenitor cells in digital ulcer-complicated systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 575-577.	0.5	8
149	The patient experience of Raynaud's phenomenon in systemic sclerosis. <i>Rheumatology</i> , 2019, 58, 18-26.	0.9	37
150	A new avenue in the pathogenesis of systemic sclerosis: the molecular interface between the endothelial and the nervous systems. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 119, 133-140.	0.4	0
151	Common measure of quality of life for people with systemic sclerosis across seven European countries: a cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1032-1038.	0.5	14
152	Assessment of hand superficial oxygenation during ischemia/reperfusion in healthy subjects versus systemic sclerosis patients by 2D near infrared spectroscopic imaging. <i>Computer Methods and Programs in Biomedicine</i> , 2018, 155, 101-108.	2.6	9
153	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 563-570.	0.5	50
154	Acute fibrinous and organizing pneumonia as initial presentation of primary Sjögren's syndrome: a case report and literature review. <i>Clinical Rheumatology</i> , 2018, 37, 2001-2005.	1.0	12
155	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. <i>Rheumatology</i> , 2018, 57, 370-381.	0.9	53
156	Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 626-628.	0.5	12
157	Functional disability and its predictors in systemic sclerosis: a study from the DeSSciper project within the EUSTAR group. <i>Rheumatology</i> , 2018, 57, 441-450.	0.9	60
158	Cross-Sectional Evaluation of Plasma Vitamin D Levels in a Large Cohort of Italian Patients with Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2018, 28, 124-129.	0.7	16
159	Review: Defining a Unified Vascular Phenotype in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2018, 70, 162-170.	2.9	48
160	Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study. <i>RMD Open</i> , 2018, 4, e000757.	1.8	28
161	European multicentre study validates enhanced liver fibrosis test as biomarker of fibrosis in systemic sclerosis. <i>Rheumatology</i> , 2018, 58, 254-259.	0.9	11
162	Vascular Leaking, a Pivotal and Early Pathogenetic Event in Systemic Sclerosis: Should the Door Be Closed?. <i>Frontiers in Immunology</i> , 2018, 9, 2045.	2.2	67

#	ARTICLE	IF	CITATIONS
163	Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC vascular working group report. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 249-252.	1.0	33
164	Brief Report: Smoking in Systemic Sclerosis: A Longitudinal European Scleroderma Trials and Research Group Study. <i>Arthritis and Rheumatology</i> , 2018, 70, 1829-1834.	2.9	15
165	Interstitial pneumonia with autoimmune features: a new classification still on the move. <i>European Respiratory Review</i> , 2018, 27, 180047.	3.0	15
166	N-Formyl Peptide Receptors Induce Radical Oxygen Production in Fibroblasts Derived From Systemic Sclerosis by Interacting With a Cleaved Form of Urokinase Receptor. <i>Frontiers in Immunology</i> , 2018, 9, 574.	2.2	16
167	Slit2/Robo4 axis may contribute to endothelial cell dysfunction and angiogenesis disturbance in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1665-1674.	0.5	25
168	Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: results of the EUSTAR group. <i>Arthritis Research and Therapy</i> , 2018, 20, 17.	1.6	75
169	The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interaction. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 135-141.	0.4	3
170	Gender differences in early systemic sclerosis patients: a report from the EULAR scleroderma trials and research group (EUSTAR) database. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 68-75.	0.4	3
171	Endothelial-to-mesenchymal transition contributes to endothelial dysfunction and dermal fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 924-934.	0.5	184
172	An expert opinion on PANDAS/PANS: highlights and controversies. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 91-98.	1.2	43
173	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1207-1218.	0.5	107
174	Proangiogenic effects of soluble Î±-Klotho on systemic sclerosis dermal microvascular endothelial cells. <i>Arthritis Research and Therapy</i> , 2017, 19, 27.	1.6	26
175	Mast cells in rheumatoid arthritis: friends or foes?. <i>Autoimmunity Reviews</i> , 2017, 16, 557-563.	2.5	52
176	The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. <i>Rheumatology International</i> , 2017, 37, 1227-1236.	1.5	22
177	Use of biologics and other novel therapies for the treatment of systemic sclerosis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 469-482.	1.3	29
178	Evidence for a Derangement of the Microvascular System in Patients with a Very Early Diagnosis of Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 1190-1197.	1.0	25
179	Cardiovascular magnetic resonance in systemic sclerosis: "Pearls and pitfalls". <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 79-85.	1.6	42
180	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1150-1158.	0.5	77

#	ARTICLE	IF	CITATIONS
181	Avascular bone necrosis: An underestimated complication of systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, e3-e5.	1.6	7
182	Update of EULAR recommendations for the treatment of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1327-1339.	0.5	794
183	Hydroxychloroquine and joint involvement in systemic sclerosis: Preliminary beneficial results from a retrospective case-control series of an EUSTAR center. <i>Joint Bone Spine</i> , 2017, 84, 747-748.	0.8	17
184	The waterpolo shoulder paradigm: results of ultrasound surveillance at poolside. <i>BMJ Open Sport and Exercise Medicine</i> , 2017, 3, e000211.	1.4	9
185	Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium. <i>Scientific Reports</i> , 2017, 7, 13293.	1.6	41
186	Points to consider in renal involvement in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v49-v52.	0.9	12
187	Points to consider for skin ulcers in systemic sclerosis. <i>Rheumatology</i> , 2017, 56, v67-v71.	0.9	59
188	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1897-1905.	0.5	410
189	Very Early Systemic Sclerosis and Pre-systemic Sclerosis: Definition, Recognition, Clinical Relevance and Future Directions. <i>Current Rheumatology Reports</i> , 2017, 19, 65.	2.1	27
190	The Measurement of the Endothelial Glycocalyx as a New Biomarker of Endothelial Derangement in Systemic Sclerosis: A Challenge for the Future. <i>Journal of Rheumatology</i> , 2017, 44, 1572-1574.	1.0	1
191	Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. <i>European Heart Journal</i> , 2017, 38, 2649-2662.	1.0	163
192	RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. <i>Respiratory Medicine</i> , 2017, 122, S14-S17.	1.3	29
193	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.0	321
194	The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. <i>Rheumatology</i> , 2017, 56, 844-852.	0.9	13
195	What have multicentre registries across the world taught us about the disease features of systemic sclerosis?. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 169-182.	1.0	18
196	Pathophysiology of Hemophilic Arthropathy. <i>Journal of Clinical Medicine</i> , 2017, 6, 63.	1.0	108
197	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 115-120.	1.0	62
198	The loss of angiogenesis in systemic sclerosis: a pivotal early pathogenetic process or just a late unavoidable event?. <i>Arthritis Research and Therapy</i> , 2017, 19, 162.	1.6	24

#	ARTICLE	IF	CITATIONS
199	Usefulness of lung ultrasound B-lines in connective tissue disease-associated interstitial lung disease: a literature review. <i>Arthritis Research and Therapy</i> , 2017, 19, 206.	1.6	96
200	Angiogenic T cell expansion correlates with severity of peripheral vascular damage in systemic sclerosis. <i>PLoS ONE</i> , 2017, 12, e0183102.	1.1	32
201	Autoimmune Tautology in a Complex Case of Polyautoimmunity: Systemic Sclerosis, Autoimmune Liver Involvement, Antiphospholipid Syndrome and Hashimoto's Thyroiditis. <i>Israel Medical Association Journal</i> , 2017, 19, 193-195.	0.1	3
202	Recommendations for infectious disease screening in migrants to Western Europe with inflammatory arthropathies before starting biologic agents. Results from a multidisciplinary task force of four European societies (SIR, SER, SIMET, SEMTSI) facing the largest impact of the flow of migrants today. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 752-765.	0.4	16
203	Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 919-928.	0.4	2
204	Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 114-121.	0.4	1
205	Long-term treatment of scleroderma-related digital ulcers with iloprost: a cohort study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 179-183.	0.4	5
206	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 1018-1028.	0.4	8
207	Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 103-109.	0.5	93
208	A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 163-169.	0.5	82
209	Introducing the Journal of Scleroderma and Related Disorders, a Challenge for the Future of Our Community. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 1-1.	1.0	1
210	Progress and Priorities in Systemic Sclerosis: The Next 10 Years " Report from the World Scleroderma Foundation. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 7-9.	1.0	3
211	Systemic sclerosis trial design moving forward. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 177-180.	1.0	42
212	Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 3717-3724.	2.0	9
213	Elucidating the burden of recurrent and chronic digital ulcers in systemic sclerosis: long-term results from the DUO Registry. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1770-1776.	0.5	72
214	Clinical characteristics and predictors of gangrene in patients with systemic sclerosis and digital ulcers in the Digital Ulcer Outcome Registry: a prospective, observational cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1736-1740.	0.5	34
215	A contribution to the debate about the possible different clinical severity between hemophilia A and B. <i>Haematologica</i> , 2016, 101, e430-e430.	1.7	0
216	Treatment of systemic sclerosis: is there any hope for the future?: Table 1. <i>RMD Open</i> , 2016, 2, e000260.	1.8	19

#	ARTICLE	IF	CITATIONS
217	Cardiovascular magnetic resonance in rheumatology: Current status and recommendations for use. <i>International Journal of Cardiology</i> , 2016, 217, 135-148.	0.8	114
218	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1975.	3.8	95
219	The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2016, 43, 1680-1686.	1.0	42
220	Is an intervention with a custom-made splint and an educational program useful on pain in patients with trapeziometacarpal joint osteoarthritis in a daily clinical setting?. <i>International Journal of Rheumatic Diseases</i> , 2016, 19, 773-780.	0.9	5
221	Premedication prevents infusion reactions and improves retention rate during infliximab treatment. <i>Clinical Rheumatology</i> , 2016, 35, 2841-2845.	1.0	15
222	Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) – A subgroup analysis of the ARIES-E clinical trial. <i>Respiratory Medicine</i> , 2016, 117, 254-263.	1.3	26
223	Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. <i>Haematologica</i> , 2016, 101, 219-225.	1.7	60
224	Efficacy of Short-term Teriparatide for Hip Osteonecrosis. <i>Journal of Rheumatology</i> , 2016, 43, 2084-2085.	1.0	3
225	Calcinosis in systemic sclerosis: subsets, distribution and complications. <i>Rheumatology</i> , 2016, 55, 1610-1614.	0.9	35
226	The crowded crossroad to angiogenesis in systemic sclerosis: where is the key to the problem?. <i>Arthritis Research and Therapy</i> , 2016, 18, 36.	1.6	16
227	Digital ulcers predict a worse disease course in patients with systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 681-686.	0.5	111
228	Severe vitamin D deficiency in patients with Kawasaki disease: a potential role in the risk to develop heart vascular abnormalities?. <i>Clinical Rheumatology</i> , 2016, 35, 1865-1872.	1.0	37
229	Systemic sclerosis-like histopathological features in the myocardium of uPAR-deficient mice. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 474-478.	0.5	14
230	Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 115-123.	1.6	84
231	Assessment, Definition, and Classification of Lower Limb Ulcers in Systemic Sclerosis: A Challenge for the Rheumatologist. <i>Journal of Rheumatology</i> , 2016, 43, 592-598.	1.0	17
232	A group of patients with Marfan's syndrome, who have finger and toe contractures, displays tendons alterations upon an ultrasound examination: are these features common among classical Marfan patients?. <i>Internal and Emergency Medicine</i> , 2016, 11, 703-711.	1.0	1
233	Osteoarthritis in the hands of Michelangelo Buonarroti. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 180-183.	1.1	13
234	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 519-532.	1.6	45

#	ARTICLE	IF	CITATIONS
235	Decreased expression of neuropilin-1 as a novel key factor contributing to peripheral microvasculopathy and defective angiogenesis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1541-1549.	0.5	38
236	Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: results from the observational study STARTER of the Italian Society for Rheumatology. <i>Rheumatology</i> , 2016, 55, 1826-1836.	0.9	36
237	Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. <i>PLoS ONE</i> , 2016, 11, e0168706.	1.1	27
238	Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 68-75.	0.4	7
239	Gait abnormalities in early rheumatoid arthritis with temporomandibular joint involvement. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 561.	0.4	1
240	A New Way of Thinking about Systemic Sclerosis: The Opportunity for a Very Early Diagnosis. <i>Israel Medical Association Journal</i> , 2016, 18, 141-3.	0.1	9
241	A candidate gene study identifies a haplotype of CD2 as novel susceptibility factor for systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 43-48.	0.4	1
242	Effects of rituximab in connective tissue disorders related interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 181-185.	0.4	20
243	Two-Dimensional near Infrared Spectroscopic Imaging of the Hand to Assess Microvascular Abnormalities in Systemic Sclerosis: A Pilot Study. <i>Journal of Near Infrared Spectroscopy</i> , 2015, 23, 59-66.	0.8	5
244	Identification of NF- κ B and PLCL2 as new susceptibility genes and highlights on a potential role of IRF8 through interferon signature modulation in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 71.	1.6	41
245	Plexin-D1/Semaphorin 3E pathway may contribute to dysregulation of vascular tone control and defective angiogenesis in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 221.	1.6	26
246	Systemic Sclerosis Sera Impair Angiogenic Performance of Dermal Microvascular Endothelial Cells: Therapeutic Implications of Cyclophosphamide. <i>PLoS ONE</i> , 2015, 10, e0130166.	1.1	24
247	Short-term effect of the combination of hyaluronic acid, chondroitin sulfate, and keratin matrix on early symptomatic knee osteoarthritis. <i>European Journal of Rheumatology</i> , 2015, 2, 106-108.	1.3	20
248	Early myocardial and skeletal muscle interstitial remodelling in systemic sclerosis: insights from extracellular volume quantification using cardiovascular magnetic resonance. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 74-80.	0.5	70
249	The new frontier in systemic sclerosis: from epigenetics to new treatments. <i>Rheumatology</i> , 2015, 54, 1757-1758.	0.9	8
250	Fetal programming and systemic sclerosis. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 213, 839.e1-839.e8.	0.7	7
251	Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis. <i>Autoimmunity Reviews</i> , 2015, 14, 314-322.	2.5	60
252	District disability, fatigue and mood disorders as determinants of health related quality of life in patients with systemic sclerosis. <i>Joint Bone Spine</i> , 2015, 82, 67-68.	0.8	4

#	ARTICLE	IF	CITATIONS
253	Intact Calibers of Retinal Vessels in Patients with Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 608-613.	1.0	16
254	Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. <i>Rheumatology</i> , 2015, 54, 792-797.	0.9	67
255	Interstitial lung disease in systemic sclerosis: where do we stand?. <i>European Respiratory Review</i> , 2015, 24, 411-419.	3.0	90
256	Digital ulcers as a sentinel sign for early internal organ involvement in very early systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 72-76.	0.9	57
257	Lymphatic endothelial progenitor cells and vascular endothelial growth factor-C in spondyloarthritis and Crohn's disease: two overlapping diseases?. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 195-200.	0.4	6
258	Ultrasonographic wrist and hand abnormalities in early psoriatic arthritis patients: correlation with clinical, dermatological, serological and genetic indices. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 330-5.	0.4	19
259	Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S148-52.	0.4	7
260	Determinants of Vitamin D Levels in Children, Adolescents, and Young Adults with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 1884-1892.	1.0	31
261	Inactivation of urokinase-type plasminogen activator receptor (uPAR) gene induces dermal and pulmonary fibrosis and peripheral microvasculopathy in mice: a new model of experimental scleroderma?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1700-1709.	0.5	72
262	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2490.	3.8	566
263	Cardiac arrhythmias and conduction defects in systemic sclerosis. <i>Rheumatology</i> , 2014, 53, 1172-1177.	0.9	83
264	Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2087-2093.	0.5	168
265	Disease Activity Improvement in Rheumatoid Arthritis Treated with Tumor Necrosis Factor- α Inhibitors Correlates with Increased Soluble Fas Levels. <i>Journal of Rheumatology</i> , 2014, 41, 1961-1965.	1.0	4
266	Rheumatological diseases and cancer: the hidden variable of radiation exposure. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2065-2068.	0.5	22
267	Evaluation of autoimmune phenomena in patients with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS). <i>Autoimmunity Reviews</i> , 2014, 13, 1236-1240.	2.5	21
268	Inherited knee disorders in the Medici family. <i>Knee</i> , 2014, 21, 2-5.	0.8	3
269	International consensus criteria for the diagnosis of Raynaud's phenomenon. <i>Journal of Autoimmunity</i> , 2014, 48-49, 60-65.	3.0	170
270	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	2.4	52

#	ARTICLE	IF	CITATIONS
271	Circulating Autoantibodies to Endothelial Progenitor Cells: Binding Characteristics and Association with Risk Factors for Atherosclerosis. PLoS ONE, 2014, 9, e97836.	1.1	6
272	From Raynaud's Phenomenon to Very Early Diagnosis of Systemic Sclerosis- The VEDOSS approach. Current Rheumatology Reviews, 2014, 9, 245-248.	0.4	15
273	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
274	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.5	1,705
275	Lung ultrasound for the screening of interstitial lung disease in very early systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 390-395.	0.5	146
276	Review: Evidence That Systemic Sclerosis Is a Vascular Disease. Arthritis and Rheumatism, 2013, 65, 1953-1962.	6.7	339
277	Treatment options in systemic sclerosis. Expert Opinion on Orphan Drugs, 2013, 1, 851-865.	0.5	0
278	The new frontiers of ultrasound in the complex world of vasculitides and scleroderma. Rheumatology, 2012, 51, vii26-vii30.	0.9	17
279	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	1.5	49
280	Validation of potential classification criteria for systemic sclerosis. Arthritis Care and Research, 2012, 64, 358-367.	1.5	77
281	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases, 2011, 70, 32-38.	0.5	394
282	An optimal decision making model for supporting week hospital management. Health Care Management Science, 2011, 14, 74-88.	1.5	40
283	Unnecessary radiation exposure from medical imaging in the rheumatology patient. Rheumatology, 2011, 50, 1537-1539.	0.9	36
284	High frequency ultrasound measurement of digital dermal thickness in systemic sclerosis. Annals of the Rheumatic Diseases, 2010, 69, 1140-1143.	0.5	82
285	Systemic Sclerosis: Clinical Manifestations. Current Rheumatology Reviews, 2010, 6, 295-304.	0.4	0
286	Lung CT Densitometry in Systemic Sclerosis. Chest, 2007, 131, 672-681.	0.4	97
287	Blood coagulation, fibrinolysis, and markers of endothelial dysfunction in systemic sclerosis. Seminars in Arthritis and Rheumatism, 2003, 32, 285-295.	1.6	133
288	Oxidative stress in Systemic Sclerosis. Molecular and Cellular Biochemistry, 1999, 196, 85-91.	1.4	48

#	ARTICLE	IF	CITATIONS
289	Raynaud's phenomenon and scleroderma dysregulated neuroendothelial control of vascular tone. Arthritis and Rheumatism, 1995, 38, 1-4.	6.7	95
290	Systemic Sclerosis. European Medical Journal Rheumatology, 0, , 100-109.	0.0	4
291	Corrigendum to: Digital pitting scars are associated with a severe disease course and death in systemic sclerosis: a study from the EUSTAR cohort. Rheumatology, 0, , .	0.9	0
292	A candidate gene study reveals association between a variant of the SRp55 splicing factor gene and systemic sclerosis. Clinical and Experimental Rheumatology, 0, , .	0.4	0